Country Overviews: market research reports

... the overall low pharmaceutical expenditure. Thesituation is further complicated by poor intellectual property protection, slow approval processes andrampant corruption. Consequently we do not expect the market to be of significant interest tomultinational pharmaceutical firms. Headline ...  |  read more...

... increase. However, we are concerned by the continued reliance onforeign grants and concessional loans. Headline Expenditure Projections Pharmaceuticals: TZS340.1bn (US$214mn) in 2011 to an expected TZS406.0bn(US$257mn) in 2012; +19.4% growth in local currency terms and ...  |  read more...

... professionals to effectively monitor the costly andtimely process, while patients would benefit from more rapidly introduced pharmaceuticals. Drugmakerswould also see higher commercial upside if the requirements were withdrawn. Headline Expenditure Projections Pharmaceuticals: PKR171.20bn (US$1.98bn) in ...  |  read more...

... healthcare, regulatory and reimbursement landscape, this report identifies the key trends in the healthcare market, as well as providing insights on the demographic landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into ...  |  read more...

... analysis on the Polish healthcare, regulatory and reimbursement landscape, this report identifies the key trends in the healthcare market, as well as providing insights on the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most ...  |  read more...

... deep segregation betweenprivate and public healthcare facilities continues to leave the vast majority of the population withoutmedical care. BMI believes this will be rectified through the creation of the National Health Insurancescheme over the next ...  |  read more...

... healthcare industry of France with the help of the ‘National Health Insurance’. The healthcare industry in France witnessed downfall as a result of the global recession. However, the overall market size of the industry is ...  |  read more...

... with measures designedto tighten public expenditure across the board, while the challenging economic outlook willnegatively affect the availability of private funding for medical products and services. Despite mediumtermconcerns, after 2012 we expect more normal growth ...  |  read more...

... new treatments. Over the longer term we expect such trends to change and activeparticipation in the Association of Southeast Asia Nations (ASEAN) Economic Community will boost itsattractiveness. Headline Expenditure Projections Pharmaceuticals: KHR718bn (US$178mn) in 2011 ...  |  read more...

... from the port and airport levy, with the changes relating to drugs, medicaldevices and equipment. Although domestic manufacturing will struggle to compete with cheap medicinesfrom India, we expect local producers to increase capacity considerably over ...  |  read more...

... –and could still be – disastrous for drugmakers operating in the market. But even Greece staying in themonetary union means the government must continue with its austerity programme. While we continue tohold to our view ...  |  read more...

... the private sector is considerable,the economy is susceptible to commodity shocks and the political outlook is uncertain. The fact thatUzbekistan’s largest privately-owned drugmaker was recently seeking opportunities in Africa, which ispredominantly a very low income ...  |  read more...